secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jazz Pharmaceuticals plc (JAZZ)
CIK:        0001232524
Form:       8-K
Filed at:   2025-10-22T23:59:59+00:00
Accession:  0001193125-25-245815
Event type: litigation
Sentiment:  neutral
Materiality: 0.80
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Jazz settles patent litigation with Avadel; grants Lumryz license, pays $90M
----------------------------------------------------------------------------

- Jazz pays $90M lump sum to Avadel and waives certain prior royalties to settle all litigation.
- Avadel gets immediate license for Lumryz in narcolepsy; license for other indications starts March 1, 2028.
- Avadel will pay 3.85% royalty on narcolepsy Lumryz sales (starting Oct 1, 2025) and 10% on other indications.
- Jazz expects ~$90M pre-tax charge in Q3 2025, funded with cash on hand.
- Jazz denies all alleged wrongdoing; both parties dismiss pending legal proceedings.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1232524/000119312525245815/0001193125-25-245815-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1232524/000119312525245815/d65147d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-245815

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer